These data strengthen iRhythm’s clinical differentiation and could accelerate adoption in high-value settings like post-ablation monitoring and prenatal cardiology. Traders should monitor for follow-up publications, payer coverage changes, or new clinical guidelines incorporating extended monitoring, which could drive volume and revenue growth.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $125.96entry
- T+1 · 7mo ago −0.41%α +0.07% · $125.44
- T+5 · 7mo ago −5.38%α −5.78% · $119.18
- T+20 · 6mo ago −9.14%α −14.09% · $114.45
- T+60 · 4mo ago −15.79%α −20.57% · $106.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
iRhythm (IRTC) presented new real-world data at HRS 2026 showing that 26% of atrial fibrillation (AF) recurrences after ablation and 60% of clinically significant arrhythmias in pregnant patients are missed with standard 24–48-hour Holter monitoring, reinforcing the clinical advantage of its 14-day Zio ambulatory ECG monitoring. The findings support broader adoption of extended monitoring to improve diagnosis, anticoagulation decisions, and maternal care.
Key Facts
- 26% of AF recurrences after ablation were detected beyond 48 hours, meaning short-term monitoring would misclassify up to 1 in 4 patients as false negatives.
- 60% of clinically significant arrhythmias in pregnant patients were first detected after 48 hours, with 13.6% having such events.
- Study included 11,051 post-ablation patients and 486 pregnant women monitored via Zio devices.
- 99.2% median analyzable time in pregnancy study confirms high data quality with Zio monitoring.
- Data challenge clinical validity of trials like OCEAN that rely on 24–48-hour monitoring for anticoagulation decisions.
Financial Impact
Potential revenue upside from increased adoption in post-ablation and obstetric cardiology markets; no direct financial figures disclosed.
Risk Factors
- Market adoption may lag despite strong evidence due to entrenched use of Holter monitors.
- Reimbursement constraints for extended monitoring in pregnancy or post-ablation settings could limit commercial impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281593 |
Track record
31 reports on IRTC
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.85% at T+60 after the Feb 25, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $90.12 Now $90.83 +0.79% settles Nov 23
- Nov 13, 20263d ago 8-K Neutral 2/10 Entry $91.91 Now $90.83 −1.18% settles Nov 20
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
- Nov 5, 202611d ago 8-K Mixed 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $90.22 to $91.91 Now $90.83 +0.68% ▲ +1.87% −0.72% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $123.99 to $134.00 Now $90.83 −26.74% ▲ +8.07% +8.79% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $108.66 Now $90.83 −16.41% No price data
- Oct 13, 20264w ago SC 13G/A Neutral 2/10 Entry $106.05 to $113.55 Now $90.83 −14.35% ▲ +7.07% +6.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers